nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisapride—CYP2A6—Methoxsalen—psoriasis	0.0773	0.0828	CbGbCtD
Cisapride—CYP2C8—Tazarotene—psoriasis	0.0591	0.0633	CbGbCtD
Cisapride—CYP3A5—Beclomethasone—psoriasis	0.0572	0.0612	CbGbCtD
Cisapride—CYP1A2—Clobetasol propionate—psoriasis	0.0561	0.0601	CbGbCtD
Cisapride—CYP2A6—Prednisolone—psoriasis	0.0376	0.0402	CbGbCtD
Cisapride—CYP2B6—Cholecalciferol—psoriasis	0.0333	0.0357	CbGbCtD
Cisapride—CYP1A2—Methoxsalen—psoriasis	0.0295	0.0316	CbGbCtD
Cisapride—CYP2D6—Hydroxyurea—psoriasis	0.0266	0.0285	CbGbCtD
Cisapride—CYP2C8—Cholecalciferol—psoriasis	0.0252	0.027	CbGbCtD
Cisapride—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0243	0.0261	CbGbCtD
Cisapride—CYP3A7—Hydrocortisone—psoriasis	0.0243	0.0261	CbGbCtD
Cisapride—CYP3A7—Cyclosporine—psoriasis	0.023	0.0246	CbGbCtD
Cisapride—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.023	0.0246	CbGbCtD
Cisapride—CYP3A5—Mycophenolate mofetil—psoriasis	0.0228	0.0244	CbGbCtD
Cisapride—CYP2A6—Dexamethasone—psoriasis	0.0222	0.0237	CbGbCtD
Cisapride—CYP2C8—Mycophenolate mofetil—psoriasis	0.0219	0.0234	CbGbCtD
Cisapride—CYP2C19—Cholecalciferol—psoriasis	0.0212	0.0227	CbGbCtD
Cisapride—CYP3A4—Calcitriol—psoriasis	0.0199	0.0213	CbGbCtD
Cisapride—CYP3A5—Hydrocortisone—psoriasis	0.0183	0.0196	CbGbCtD
Cisapride—CYP2C9—Cholecalciferol—psoriasis	0.0176	0.0189	CbGbCtD
Cisapride—CYP2C8—Hydrocortisone—psoriasis	0.0176	0.0188	CbGbCtD
Cisapride—CYP3A5—Cyclosporine—psoriasis	0.0172	0.0185	CbGbCtD
Cisapride—CYP2C8—Cyclosporine—psoriasis	0.0166	0.0178	CbGbCtD
Cisapride—CYP2D6—Cholecalciferol—psoriasis	0.0161	0.0172	CbGbCtD
Cisapride—CYP3A4—Methoxsalen—psoriasis	0.0155	0.0166	CbGbCtD
Cisapride—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0151	0.0162	CbGbCtD
Cisapride—CYP3A7—Dexamethasone—psoriasis	0.0151	0.0162	CbGbCtD
Cisapride—CYP2C19—Prednisone—psoriasis	0.0147	0.0157	CbGbCtD
Cisapride—CYP2B6—Dexamethasone—psoriasis	0.0144	0.0154	CbGbCtD
Cisapride—CYP2C19—Cyclosporine—psoriasis	0.0139	0.0149	CbGbCtD
Cisapride—CYP2C9—Cyclosporine—psoriasis	0.0116	0.0124	CbGbCtD
Cisapride—CYP3A5—Dexamethasone—psoriasis	0.0114	0.0122	CbGbCtD
Cisapride—CYP2C8—Dexamethasone—psoriasis	0.0109	0.0117	CbGbCtD
Cisapride—CYP2D6—Cyclosporine—psoriasis	0.0106	0.0113	CbGbCtD
Cisapride—CYP3A4—Cholecalciferol—psoriasis	0.0102	0.011	CbGbCtD
Cisapride—CYP2C19—Dexamethasone—psoriasis	0.00916	0.00981	CbGbCtD
Cisapride—CYP3A4—Mycophenolate mofetil—psoriasis	0.00888	0.00951	CbGbCtD
Cisapride—CYP3A4—Triamcinolone—psoriasis	0.00888	0.00951	CbGbCtD
Cisapride—CYP2C9—Dexamethasone—psoriasis	0.00762	0.00816	CbGbCtD
Cisapride—CYP3A4—Betamethasone—psoriasis	0.00761	0.00816	CbGbCtD
Cisapride—CYP3A4—Prednisolone—psoriasis	0.00751	0.00805	CbGbCtD
Cisapride—CYP3A4—Hydrocortisone—psoriasis	0.00712	0.00763	CbGbCtD
Cisapride—CYP3A4—Prednisone—psoriasis	0.0071	0.0076	CbGbCtD
Cisapride—CYP2D6—Dexamethasone—psoriasis	0.00697	0.00746	CbGbCtD
Cisapride—CYP3A4—Cyclosporine—psoriasis	0.00673	0.0072	CbGbCtD
Cisapride—CYP3A4—Dexamethasone—psoriasis	0.00443	0.00474	CbGbCtD
Cisapride—HTR3A—Transmembrane transport of small molecules—CARM1—psoriasis	0.000144	0.00217	CbGpPWpGaD
Cisapride—DRD2—G alpha (i) signalling events—CCL20—psoriasis	0.000138	0.00208	CbGpPWpGaD
Cisapride—HTR3A—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000136	0.00204	CbGpPWpGaD
Cisapride—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000133	0.002	CbGpPWpGaD
Cisapride—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000132	0.00198	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—HCAR2—psoriasis	0.000128	0.00192	CbGpPWpGaD
Cisapride—HTR3A—SIDS Susceptibility Pathways—JUN—psoriasis	0.000126	0.0019	CbGpPWpGaD
Cisapride—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000126	0.00189	CbGpPWpGaD
Cisapride—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000124	0.00187	CbGpPWpGaD
Cisapride—HTR3A—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000121	0.00183	CbGpPWpGaD
Cisapride—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000118	0.00177	CbGpPWpGaD
Cisapride—HTR2B—GPCR ligand binding—CCL20—psoriasis	0.000117	0.00177	CbGpPWpGaD
Cisapride—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000116	0.00175	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—HCAR2—psoriasis	0.000116	0.00175	CbGpPWpGaD
Cisapride—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	0.000114	0.00172	CbGpPWpGaD
Cisapride—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000113	0.00171	CbGpPWpGaD
Cisapride—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000113	0.0017	CbGpPWpGaD
Cisapride—HTR3A—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.00011	0.00166	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00011	0.00165	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000108	0.00163	CbGpPWpGaD
Cisapride—HTR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000106	0.0016	CbGpPWpGaD
Cisapride—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000104	0.00156	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—HCAR2—psoriasis	0.000103	0.00155	CbGpPWpGaD
Cisapride—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000102	0.00153	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—CCL20—psoriasis	9.47e-05	0.00143	CbGpPWpGaD
Cisapride—HTR3A—SIDS Susceptibility Pathways—TNF—psoriasis	9.44e-05	0.00142	CbGpPWpGaD
Cisapride—KCNH2—SIDS Susceptibility Pathways—CXCL8—psoriasis	9.4e-05	0.00141	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—HCAR2—psoriasis	9.36e-05	0.00141	CbGpPWpGaD
Cisapride—HTR2A—SIDS Susceptibility Pathways—IL10—psoriasis	9.31e-05	0.0014	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—HCAR2—psoriasis	9.1e-05	0.00137	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—CCL20—psoriasis	9.07e-05	0.00137	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—HCAR2—psoriasis	8.95e-05	0.00135	CbGpPWpGaD
Cisapride—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	8.79e-05	0.00132	CbGpPWpGaD
Cisapride—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.75e-05	0.00132	CbGpPWpGaD
Cisapride—KCNH2—SIDS Susceptibility Pathways—JUN—psoriasis	8.74e-05	0.00131	CbGpPWpGaD
Cisapride—KCNH2—SIDS Susceptibility Pathways—NFKB1—psoriasis	8.41e-05	0.00127	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—CCL20—psoriasis	8.36e-05	0.00126	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—HCAR2—psoriasis	8.26e-05	0.00124	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—CCL20—psoriasis	8.23e-05	0.00124	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—HCAR2—psoriasis	8.13e-05	0.00122	CbGpPWpGaD
Cisapride—HTR4—GPCR ligand binding—CXCL8—psoriasis	8.08e-05	0.00122	CbGpPWpGaD
Cisapride—KCNH2—SIDS Susceptibility Pathways—VEGFA—psoriasis	7.63e-05	0.00115	CbGpPWpGaD
Cisapride—HTR3A—SIDS Susceptibility Pathways—IL6—psoriasis	7.61e-05	0.00115	CbGpPWpGaD
Cisapride—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	7.31e-05	0.0011	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—NDUFA5—psoriasis	7.04e-05	0.00106	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—HCAR2—psoriasis	6.85e-05	0.00103	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—CCL20—psoriasis	6.64e-05	0.000999	CbGpPWpGaD
Cisapride—KCNH2—SIDS Susceptibility Pathways—TNF—psoriasis	6.54e-05	0.000984	CbGpPWpGaD
Cisapride—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	6.46e-05	0.000972	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—NDUFA5—psoriasis	6.46e-05	0.000972	CbGpPWpGaD
Cisapride—DRD2—Circadian rythm related genes—LEP—psoriasis	6.36e-05	0.000957	CbGpPWpGaD
Cisapride—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	6.32e-05	0.000951	CbGpPWpGaD
Cisapride—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	6.08e-05	0.000915	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—CCL20—psoriasis	6.03e-05	0.000907	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—CYP2S1—psoriasis	5.99e-05	0.000901	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—TAGAP—psoriasis	5.94e-05	0.000894	CbGpPWpGaD
Cisapride—DRD2—Circadian rythm related genes—NOS2—psoriasis	5.92e-05	0.000892	CbGpPWpGaD
Cisapride—DRD2—Circadian rythm related genes—PPARG—psoriasis	5.54e-05	0.000834	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—HCAR2—psoriasis	5.53e-05	0.000832	CbGpPWpGaD
Cisapride—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	5.52e-05	0.00083	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—CYP2S1—psoriasis	5.49e-05	0.000826	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—CCL20—psoriasis	5.35e-05	0.000806	CbGpPWpGaD
Cisapride—KCNH2—SIDS Susceptibility Pathways—IL6—psoriasis	5.28e-05	0.000794	CbGpPWpGaD
Cisapride—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	5.21e-05	0.000784	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—NDUFA5—psoriasis	5.21e-05	0.000784	CbGpPWpGaD
Cisapride—HTR2A—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.09e-05	0.000766	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—NDUFA5—psoriasis	5.09e-05	0.000766	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—SOCS1—psoriasis	4.99e-05	0.000752	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—HCAR2—psoriasis	4.88e-05	0.000734	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—CCL20—psoriasis	4.86e-05	0.000732	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—HCAR2—psoriasis	4.8e-05	0.000723	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—TAGAP—psoriasis	4.79e-05	0.000722	CbGpPWpGaD
Cisapride—HTR4—Signaling by GPCR—TYK2—psoriasis	4.76e-05	0.000717	CbGpPWpGaD
Cisapride—HTR2A—SIDS Susceptibility Pathways—JUN—psoriasis	4.73e-05	0.000713	CbGpPWpGaD
Cisapride—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.73e-05	0.000712	CbGpPWpGaD
Cisapride—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.73e-05	0.000712	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—CCL20—psoriasis	4.72e-05	0.000711	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—CCL20—psoriasis	4.65e-05	0.0007	CbGpPWpGaD
Cisapride—HTR4—GPCR downstream signaling—CXCL8—psoriasis	4.57e-05	0.000687	CbGpPWpGaD
Cisapride—HTR2A—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.56e-05	0.000686	CbGpPWpGaD
Cisapride—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	4.52e-05	0.000681	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—CYP2S1—psoriasis	4.43e-05	0.000667	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—NDUFA5—psoriasis	4.41e-05	0.000664	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—CYP2S1—psoriasis	4.33e-05	0.000652	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—CCL20—psoriasis	4.29e-05	0.000646	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—TAGAP—psoriasis	4.23e-05	0.000637	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—CCL20—psoriasis	4.22e-05	0.000635	CbGpPWpGaD
Cisapride—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.16e-05	0.000627	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—TAGAP—psoriasis	4.16e-05	0.000627	CbGpPWpGaD
Cisapride—HTR4—Signaling by GPCR—CXCL8—psoriasis	4.15e-05	0.000624	CbGpPWpGaD
Cisapride—HTR2A—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.14e-05	0.000623	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.11e-05	0.000619	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—NDUFA5—psoriasis	3.94e-05	0.000592	CbGpPWpGaD
Cisapride—DRD2—Circadian rythm related genes—JUN—psoriasis	3.93e-05	0.000591	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—CYP2S1—psoriasis	3.75e-05	0.000564	CbGpPWpGaD
Cisapride—DRD2—G alpha (i) signalling events—CXCL8—psoriasis	3.73e-05	0.000561	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—APOE—psoriasis	3.69e-05	0.000555	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—LEP—psoriasis	3.69e-05	0.000555	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.67e-05	0.000552	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—NDUFA5—psoriasis	3.62e-05	0.000545	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—NDUFA5—psoriasis	3.59e-05	0.00054	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CCL20—psoriasis	3.56e-05	0.000536	CbGpPWpGaD
Cisapride—HTR2A—SIDS Susceptibility Pathways—TNF—psoriasis	3.54e-05	0.000534	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—NFKBIA—psoriasis	3.43e-05	0.000517	CbGpPWpGaD
Cisapride—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.36e-05	0.000506	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—CYP2S1—psoriasis	3.35e-05	0.000504	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.35e-05	0.000504	CbGpPWpGaD
Cisapride—HTR2B—GPCR ligand binding—CXCL8—psoriasis	3.17e-05	0.000477	CbGpPWpGaD
Cisapride—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	3.16e-05	0.000475	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—CYP2S1—psoriasis	3.08e-05	0.000463	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—NDUFA5—psoriasis	3.07e-05	0.000462	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—CYP2S1—psoriasis	3.05e-05	0.000459	CbGpPWpGaD
Cisapride—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.96e-05	0.000446	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—CARM1—psoriasis	2.92e-05	0.00044	CbGpPWpGaD
Cisapride—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.92e-05	0.000439	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CCL20—psoriasis	2.87e-05	0.000432	CbGpPWpGaD
Cisapride—HTR2A—SIDS Susceptibility Pathways—IL6—psoriasis	2.86e-05	0.000431	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.86e-05	0.00043	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—TYK2—psoriasis	2.81e-05	0.000423	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—CARM1—psoriasis	2.68e-05	0.000404	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—CYP2S1—psoriasis	2.61e-05	0.000393	CbGpPWpGaD
Cisapride—DRD2—Circadian rythm related genes—TP53—psoriasis	2.59e-05	0.00039	CbGpPWpGaD
Cisapride—HTR2C—GPCR ligand binding—CXCL8—psoriasis	2.56e-05	0.000385	CbGpPWpGaD
Cisapride—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.55e-05	0.000384	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CCL20—psoriasis	2.53e-05	0.000381	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CCL20—psoriasis	2.49e-05	0.000375	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—CXCL8—psoriasis	2.45e-05	0.000369	CbGpPWpGaD
Cisapride—DRD2—Circadian rythm related genes—IL6—psoriasis	2.37e-05	0.000357	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—NDUFA5—psoriasis	2.37e-05	0.000356	CbGpPWpGaD
Cisapride—HTR4—Signaling by GPCR—IL6—psoriasis	2.33e-05	0.000351	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—JUN—psoriasis	2.28e-05	0.000343	CbGpPWpGaD
Cisapride—DRD2—GPCR ligand binding—CXCL8—psoriasis	2.26e-05	0.00034	CbGpPWpGaD
Cisapride—HTR2A—GPCR ligand binding—CXCL8—psoriasis	2.22e-05	0.000334	CbGpPWpGaD
Cisapride—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.21e-05	0.000333	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—NFKB1—psoriasis	2.19e-05	0.00033	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—CARM1—psoriasis	2.16e-05	0.000326	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—CARM1—psoriasis	2.11e-05	0.000318	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—CYP2S1—psoriasis	2.01e-05	0.000303	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—VEGFA—psoriasis	1.99e-05	0.000299	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—STAT3—psoriasis	1.97e-05	0.000296	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.97e-05	0.000296	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—SOCS1—psoriasis	1.96e-05	0.000295	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—TYK2—psoriasis	1.87e-05	0.000281	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—CARM1—psoriasis	1.83e-05	0.000276	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—CAT—psoriasis	1.8e-05	0.000271	CbGpPWpGaD
Cisapride—HTR2B—GPCR downstream signaling—CXCL8—psoriasis	1.79e-05	0.00027	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.75e-05	0.000264	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.71e-05	0.000258	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—CAT—psoriasis	1.65e-05	0.000248	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—CARM1—psoriasis	1.63e-05	0.000246	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—CXCL8—psoriasis	1.63e-05	0.000245	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.6e-05	0.000241	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—SOCS1—psoriasis	1.58e-05	0.000238	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.53e-05	0.00023	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—TYK2—psoriasis	1.51e-05	0.000227	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—CARM1—psoriasis	1.5e-05	0.000226	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—TP53—psoriasis	1.5e-05	0.000226	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—CARM1—psoriasis	1.49e-05	0.000224	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—LEP—psoriasis	1.45e-05	0.000218	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—APOE—psoriasis	1.45e-05	0.000218	CbGpPWpGaD
Cisapride—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	1.45e-05	0.000218	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—APOE—psoriasis	1.4e-05	0.00021	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—SOCS1—psoriasis	1.4e-05	0.00021	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.39e-05	0.00021	CbGpPWpGaD
Cisapride—HTR4—Signaling Pathways—IL6—psoriasis	1.38e-05	0.000207	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—SOCS1—psoriasis	1.37e-05	0.000207	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.37e-05	0.000206	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—NFKBIA—psoriasis	1.35e-05	0.000203	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—TYK2—psoriasis	1.33e-05	0.0002	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—CAT—psoriasis	1.33e-05	0.0002	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—CXCL8—psoriasis	1.31e-05	0.000198	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—TYK2—psoriasis	1.31e-05	0.000197	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—CAT—psoriasis	1.3e-05	0.000196	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—APOE—psoriasis	1.28e-05	0.000193	CbGpPWpGaD
Cisapride—DRD2—GPCR downstream signaling—CXCL8—psoriasis	1.28e-05	0.000192	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—CARM1—psoriasis	1.27e-05	0.000192	CbGpPWpGaD
Cisapride—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	1.26e-05	0.000189	CbGpPWpGaD
Cisapride—CYP3A7—Metabolism—PPARG—psoriasis	1.22e-05	0.000183	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.19e-05	0.000179	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—APOE—psoriasis	1.17e-05	0.000176	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—LEP—psoriasis	1.17e-05	0.000176	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—CXCL8—psoriasis	1.16e-05	0.000174	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—CXCL8—psoriasis	1.14e-05	0.000172	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—CAT—psoriasis	1.13e-05	0.00017	CbGpPWpGaD
Cisapride—CYP2A6—Metabolism—PPARG—psoriasis	1.12e-05	0.000168	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—TYK2—psoriasis	1.1e-05	0.000166	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—NFKBIA—psoriasis	1.09e-05	0.000164	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—APOE—psoriasis	1.03e-05	0.000156	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—LEP—psoriasis	1.03e-05	0.000155	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—APOE—psoriasis	1.03e-05	0.000155	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—APOE—psoriasis	1.01e-05	0.000153	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—LEP—psoriasis	1.01e-05	0.000153	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—APOE—psoriasis	1.01e-05	0.000152	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—CAT—psoriasis	1.01e-05	0.000151	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—CARM1—psoriasis	9.83e-06	0.000148	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—CXCL8—psoriasis	9.61e-06	0.000145	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—NFKBIA—psoriasis	9.6e-06	0.000144	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—NFKBIA—psoriasis	9.44e-06	0.000142	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—CAT—psoriasis	9.25e-06	0.000139	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—CAT—psoriasis	9.17e-06	0.000138	CbGpPWpGaD
Cisapride—HTR2B—Signaling by GPCR—IL6—psoriasis	9.14e-06	0.000138	CbGpPWpGaD
Cisapride—CYP2B6—Metabolism—PPARG—psoriasis	9e-06	0.000136	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—JUN—psoriasis	8.94e-06	0.000135	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—TYK2—psoriasis	8.91e-06	0.000134	CbGpPWpGaD
Cisapride—CYP3A5—Metabolism—PPARG—psoriasis	8.8e-06	0.000132	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—APOE—psoriasis	8.75e-06	0.000132	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—NFKB1—psoriasis	8.6e-06	0.000129	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—TYK2—psoriasis	7.86e-06	0.000118	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—CAT—psoriasis	7.83e-06	0.000118	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—APOE—psoriasis	7.81e-06	0.000118	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—VEGFA—psoriasis	7.81e-06	0.000118	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—CXCL8—psoriasis	7.76e-06	0.000117	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—TYK2—psoriasis	7.73e-06	0.000116	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—STAT3—psoriasis	7.73e-06	0.000116	CbGpPWpGaD
Cisapride—CYP2C8—Metabolism—PPARG—psoriasis	7.62e-06	0.000115	CbGpPWpGaD
Cisapride—HTR2C—Signaling by GPCR—IL6—psoriasis	7.37e-06	0.000111	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—JUN—psoriasis	7.21e-06	0.000109	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—APOE—psoriasis	7.18e-06	0.000108	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—APOE—psoriasis	7.12e-06	0.000107	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—NFKB1—psoriasis	6.94e-06	0.000104	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—CXCL8—psoriasis	6.84e-06	0.000103	CbGpPWpGaD
Cisapride—CYP2C19—Metabolism—PPARG—psoriasis	6.8e-06	0.000102	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—CXCL8—psoriasis	6.73e-06	0.000101	CbGpPWpGaD
Cisapride—DRD2—Signaling by GPCR—IL6—psoriasis	6.51e-06	9.8e-05	CbGpPWpGaD
Cisapride—HTR2A—Signaling by GPCR—IL6—psoriasis	6.4e-06	9.64e-05	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—JUN—psoriasis	6.36e-06	9.58e-05	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—VEGFA—psoriasis	6.3e-06	9.48e-05	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—JUN—psoriasis	6.26e-06	9.42e-05	CbGpPWpGaD
Cisapride—CYP2D6—Metabolism—PPARG—psoriasis	6.26e-06	9.42e-05	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—STAT3—psoriasis	6.24e-06	9.39e-05	CbGpPWpGaD
Cisapride—CYP2C9—Metabolism—PPARG—psoriasis	6.2e-06	9.34e-05	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—NFKB1—psoriasis	6.12e-06	9.22e-05	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—APOE—psoriasis	6.09e-06	9.16e-05	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—CAT—psoriasis	6.05e-06	9.1e-05	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—NFKB1—psoriasis	6.03e-06	9.07e-05	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—TP53—psoriasis	5.9e-06	8.88e-05	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—VEGFA—psoriasis	5.56e-06	8.37e-05	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—STAT3—psoriasis	5.5e-06	8.28e-05	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—VEGFA—psoriasis	5.47e-06	8.23e-05	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—STAT3—psoriasis	5.42e-06	8.15e-05	CbGpPWpGaD
Cisapride—HTR2B—Signaling Pathways—IL6—psoriasis	5.4e-06	8.13e-05	CbGpPWpGaD
Cisapride—CYP1A2—Metabolism—PPARG—psoriasis	5.3e-06	7.98e-05	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—TP53—psoriasis	4.76e-06	7.16e-05	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—APOE—psoriasis	4.7e-06	7.07e-05	CbGpPWpGaD
Cisapride—HTR2C—Signaling Pathways—IL6—psoriasis	4.36e-06	6.56e-05	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—TP53—psoriasis	4.2e-06	6.32e-05	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—TP53—psoriasis	4.13e-06	6.22e-05	CbGpPWpGaD
Cisapride—CYP3A4—Metabolism—PPARG—psoriasis	4.09e-06	6.16e-05	CbGpPWpGaD
Cisapride—DRD2—Signaling Pathways—IL6—psoriasis	3.84e-06	5.79e-05	CbGpPWpGaD
Cisapride—HTR2A—Signaling Pathways—IL6—psoriasis	3.78e-06	5.69e-05	CbGpPWpGaD
